Document:

Exhibit
4.11

 

PRE-FUNDED
COMMON STOCK PURCHASE WARRANT

 

ENSYSCE
BIOSCIENCES, INC. 

 

	Warrant
    Shares: 	 _______________	 	Issue
    Date: [●], 2022
	 	 	 	 
	 	 	 	Initial
    Exercise Date: [●], 2022

 

THIS
PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, ______________ or
its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the
conditions hereinafter set forth, at any time on or after the date set forth above (the “Initial Exercise Date”) and until this Warrant is exercised in full (the “Termination Date”) but not thereafter, to
subscribe for and purchase from Ensysce Biosciences, Inc., a Delaware corporation (the “Company”), up to
______________ shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. The
purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section
2(b).

 

Section
1. Definitions. In addition to the terms defined elsewhere in this Warrant, the following terms have the meanings indicated
in this Section 1:

 

“Affiliate”
means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control
with a Person, as such terms are used in and construed under Rule 405 under the Securities Act.

 

“Bid
Price” means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock
is then listed or quoted on a Trading Market, the bid price of the Common Stock for the time in question (or the nearest preceding date)
on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg (based on a Trading Day from 9:30 a.m.
(New York City time) to 4:02 p.m. (New York City time)), (b) if OTCQB or OTCQX is not a Trading Market, the volume weighted average price
of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not then
listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on The Pink Open Market (or a similar
organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common Stock so reported,
or (d) in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser selected in good
faith by the Holders of a majority in interest of the Warrants then outstanding and reasonably acceptable to the Company, the reasonable
fees and expenses of which shall be paid by the Company.

 

“Commission”
means the United States Securities and Exchange Commission.

 

“Common
Stock” means the common stock of the Company, par value $0.0001 per share, and any other class of securities into which such
securities may hereafter be reclassified or changed.

 

    	 

     

    

 

“Common
Stock Equivalents” means any securities of the Company or the Subsidiaries which would entitle the holder thereof to acquire
at any time Common Stock, including, without limitation, any debt, preferred stock, right, option, warrant or other instrument that is
at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock.

 

“Exchange
Act” means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.

 

“Person”
means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability
company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.

 

“Registration
Statement” means the effective registration statement on Form S-1 filed with Commission (File No. 333-268038), including all
information, documents and exhibits filed with or incorporated by reference into such registration statement, as amended from time to
time, which registers the sale the Warrants and the Warrant Shares, among others, and includes any Rule 462(b) Registration Statement.

 

“Securities
Act” means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.

 

“Subsidiaries”
means the subsidiaries of the Company set forth on Exhibit 21.1 to the Registration Statement and shall, where applicable, also include
any direct or indirect subsidiary of the Company formed or acquired after the date hereof.

 

“Trading
Day” means a day on which the Common Stock is traded on a Trading Market.

 

“Trading
Market” means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on the date
in question: the NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market or the New York
Stock Exchange (or any successors to any of the foregoing).

 

“Transfer
Agent” means Continental Stock Transfer & Trust Company, the current transfer agent of the Company, with a mailing address
of 1 State St 30th floor, New York, NY 10004, and any successor transfer agent of the Company.

 

“Underwriting
Agreement” means that certain Underwriting Agreement, dated as of [●], 2022 by and between the Company and Lake Street Capital
Markets, LLC.

 

    	-2-

     

    

 

“VWAP”
means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed
or quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding date)
on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg (based on a Trading Day from 9:30 a.m.
(New York City time) to 4:02 p.m. (New York City time)), (b) if OTCQB or OTCQX is not a Trading Market, the volume weighted average price
of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not then
listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on The Pink Open Market (or a similar
organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common Stock so reported,
or (d) in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser selected in good
faith by the Holders of a majority in interest of the Warrants then outstanding and reasonably acceptable to the Company, the reasonable
fees and expenses of which shall be paid by the Company.

 

“Warrants”
means this Warrant and other pre-funded Common Stock purchase warrants issued by the Company pursuant to the Registration
Statement.

 

Section
2. Exercise.

 

a)
Exercise of Warrant. Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any time
or times on or after the Initial Exercise Date and on or before the Termination Date by delivery to the Company of a duly executed PDF
copy submitted by e-mail (or e-mail attachment) of the Notice of Exercise in the form attached hereto as Annex A (the “Notice
of Exercise”). Within the earlier of (i) two (2) Trading Days and (ii) the number of Trading Days comprising the Standard Settlement
Period (as defined in Section 2(d)(i) herein) following the date of exercise as aforesaid, the Holder shall deliver the aggregate Exercise
Price for the Warrant Shares specified in the applicable Notice of Exercise by wire transfer or cashier’s check drawn on a United
States bank, in either case in immediately available funds, unless the cashless exercise procedure specified in Section 2(c) below is
specified in the applicable Notice of Exercise. No ink-original Notice of Exercise shall be required, nor shall any medallion guarantee
(or other type of guarantee or notarization) of any Notice of Exercise be required. The Company shall have no obligation to inquire with
respect to or otherwise confirm the authenticity of the signature(s) contained on any Notice of Exercise nor the authority of the person
so executing such Notice of Exercise. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically
surrender this Warrant to the Company until the Holder has purchased all of the Warrant Shares available hereunder and the Warrant has
been exercised in full, in which case, the Holder shall surrender this Warrant to the Company for cancellation within three (3) Trading
Days of the date on which the final Notice of Exercise is delivered to the Company. Partial exercises of this Warrant resulting in purchases
of a portion of the total number of Warrant Shares available hereunder shall have the effect of lowering the outstanding number of Warrant
Shares purchasable hereunder in an amount equal to the applicable number of Warrant Shares purchased. The Holder and the Company shall
maintain records showing the number of Warrant Shares purchased and the date of such purchases. The Company shall deliver any objection
to any Notice of Exercise within one (1) Trading Day of receipt of such notice. The Holder and any assignee, by acceptance of this
Warrant, acknowledge and agree that, by reason of the provisions of this paragraph, following the purchase of a portion of the Warrant
Shares hereunder, the number of Warrant Shares available for purchase hereunder at any given time may be less than the amount stated
on the face hereof.

 

    	-3-

     

    

 

b)
Exercise Price. The aggregate exercise price of this Warrant, except for a nominal exercise price of $0.0001 per Warrant Share, was
pre-funded to the Company on or prior to the Initial Exercise Date and, consequently, no additional consideration (other than the nominal
exercise price of $0.0001 per Warrant Share) shall be required to be paid by the Holder to any Person to effect any exercise of this Warrant.
The Holder shall not be entitled to the return or refund of all, or any portion, of such pre-paid aggregate exercise price under any circumstance
or for any reason whatsoever. The remaining unpaid exercise price per share of Common Stock under this Warrant shall be $0.0001, subject to adjustment hereunder
(the “Exercise Price”).

 

c)
Cashless Exercise. This Warrant may also be exercised, in
whole or in part, at such time by means of a “cashless exercise” in which the Holder shall be entitled to receive a number
of Warrant Shares equal to the quotient obtained by dividing [(A-B) (X)] by (A), where:

 

	 	(A)	=	as
applicable: (i) the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise if such Notice of Exercise
is (1) both executed and delivered pursuant to Section 2(a) hereof on a day that is not a Trading Day or (2) both executed and delivered
pursuant to Section 2(a) hereof on a Trading Day prior to the opening of “regular trading hours” (as defined in Rule 600(b)
of Regulation NMS promulgated under the federal securities laws) on such Trading Day, (ii) at the option of the Holder, either (y) the
VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise or (z) the Bid Price of the Common Stock
on the principal Trading Market as reported by Bloomberg L.P. (“Bloomberg”) as of the time of the Holder’s execution
of the applicable Notice of Exercise if such Notice of Exercise is executed during “regular trading hours” on a Trading Day
and is delivered within two (2) hours thereafter (including until two (2) hours after the close of “regular trading hours”
on a Trading Day) pursuant to Section 2(a) hereof or (iii) the VWAP on the date of the applicable Notice of Exercise if the date of such
Notice of Exercise is a Trading Day and such Notice of Exercise is both executed and delivered pursuant to Section 2(a) hereof after
the close of “regular trading hours” on such Trading Day;
	 	 	 	 
	 	(B)	=	the
Exercise Price of this Warrant, as adjusted hereunder; and 
	 	 	 	 
	 	(X)	=
	the
    number of Warrant Shares that would be issuable upon exercise of this Warrant in accordance with the terms of this Warrant if such
    exercise were by means of a cash exercise rather than a cashless exercise.

 

If
Warrant Shares are issued in such a cashless exercise, the parties acknowledge and agree that in accordance with Section 3(a)(9) of the
Securities Act, the Warrant Shares shall take on the registered characteristics of the Warrants being exercised. The Company agrees not
to take any position contrary to this Section 2(c).

 

    	-4-

     

    

 

d)
Mechanics of Exercise.

 

i.
Delivery of Warrant Shares Upon Exercise. The Company shall cause the Warrant Shares purchased hereunder to be transmitted by
the Transfer Agent to the Holder by crediting the account of the Holder’s or its designee’s balance account with The Depository
Trust Company through its Deposit or Withdrawal at Custodian system (“DWAC”) if the Company’s transfer agent
is then a participant in such system and either (A) there is an effective registration statement permitting the issuance of the Warrant
Shares to or resale of the Warrant Shares by the Holder or (B) this Warrant is being exercised via cashless exercise, and otherwise by
physical delivery of a certificate, registered in the Company’s share register in the name of the Holder or its designee, for the
number of Warrant Shares to which the Holder is entitled pursuant to such exercise to the address specified by the Holder in the Notice
of Exercise by the date that is the earliest of (i) two (2) Trading Days after the delivery to the Company of the Notice of Exercise,
(ii) one (1) Trading Day after delivery of the aggregate Exercise Price to the Company and (iii) the number of Trading Days comprising
the Standard Settlement Period after the delivery to the Company of the Notice of Exercise (such date, the “Warrant Share Delivery
Date”). Upon delivery of the Notice of Exercise, the Holder shall be deemed for all corporate purposes to have become the holder
of record of the Warrant Shares with respect to which this Warrant has been exercised, irrespective of the date of delivery of the Warrant
Shares, provided that the Company shall have received payment of the aggregate Exercise Price (other than in the case of a cashless exercise)
is received within the earlier of (i) two (2) Trading Days and (ii) the number of Trading Days comprising the Standard Settlement Period
following delivery of the Notice of Exercise. If the Company fails for any reason to deliver to the Holder the Warrant Shares subject
to a Notice of Exercise by the Warrant Share Delivery Date, the Company shall pay to the Holder, in cash, as liquidated damages and not
as a penalty, for each $1,000 of Warrant Shares subject to such exercise (based on the VWAP of the Common Stock on the date of the applicable
Notice of Exercise), $10 per Trading Day (increasing to $20 per Trading Day on the third Trading Day after the Warrant Share Delivery
Date) for each Trading Day after such Warrant Share Delivery Date until such Warrant Shares are delivered or Holder rescinds such exercise.
The Company agrees to maintain a transfer agent that is a participant in the FAST program so long as this Warrant remains outstanding
and exercisable. As used herein, “Standard Settlement Period” means the standard settlement period, expressed in a
number of Trading Days, on the Company’s primary Trading Market with respect to the Common Stock as in effect on the date of the
delivery of the Notice of Exercise. Notwithstanding the foregoing, with respect to any Notice(s) of Exercise delivered on or prior to 12:00 p.m. (New
York City time) on the Initial Exercise Date, which may be delivered at any time after the time of execution of the Underwriting Agreement,
the Company agrees to deliver the Warrant Shares subject to such notice(s) by 4:00 p.m. (New York City time) on the Initial Exercise Date
and the Initial Exercise Date shall be the Warrant Share Delivery Date for purposes hereunder, provided that payment of the aggregate
Exercise Price (other than in the case of a cashless exercise) is received by such Warrant Share Delivery Date.

 

    	-5-

     

    

 

ii.
Delivery of New Warrants Upon Exercise. If this Warrant shall have been exercised in part, the Company shall, at the request of
a Holder and upon surrender of this Warrant, at the time of delivery of the Warrant Shares, deliver to the Holder a new Warrant evidencing
the rights of the Holder to purchase the unpurchased Warrant Shares remaining available under this Warrant, which new Warrant shall in
all other respects be identical with this Warrant.

 

iii.
Rescission Rights. If the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares pursuant to Section
2(d)(i) by the Warrant Share Delivery Date, then the Holder will have the right to rescind such exercise.

 

iv.
Compensation for Buy-In on Failure to Timely Deliver Warrant Shares Upon Exercise. In addition to any other rights available to
the Holder, if the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares in accordance with the provisions
of Section 2(d)(i) above pursuant to an exercise on or before the Warrant Share Delivery Date, and if after such date the Holder is required
by its broker to purchase (in an open market transaction or otherwise) or the Holder’s brokerage firm otherwise purchases, shares
of Common Stock to deliver in satisfaction of a sale by the Holder of the Warrant Shares which the Holder anticipated receiving upon
such exercise (a “Buy-In”), then the Company shall (A) pay in cash to the Holder the amount, if any, by which (x)
the Holder’s total purchase price (including reasonable and customary brokerage commissions, if any) for the shares of Common Stock
so purchased exceeds (y) the amount obtained by multiplying (1) the number of Warrant Shares that the Company was required to deliver
to the Holder in connection with the exercise at issue times (2) the price at which the sell order giving rise to such purchase obligation
was executed, and (B) at the option of the Holder, either reinstate the portion of the Warrant and equivalent number of Warrant Shares
for which such exercise was not honored (in which case such exercise shall be deemed rescinded) or deliver to the Holder the number of
shares of Common Stock that would have been issued had the Company timely complied with its exercise and delivery obligations hereunder.
For example, if the Holder purchases Common Stock having a total purchase price of $11,000 to cover a Buy-In with respect to an attempted
exercise of shares of Common Stock with an aggregate sale price giving rise to such purchase obligation of $10,000, under clause (A)
of the immediately preceding sentence the Company shall be required to pay the Holder $1,000. The Holder shall provide the Company written
notice indicating the amounts payable to the Holder in respect of the Buy-In and, upon request of the Company, evidence of the amount
of such loss. Nothing herein shall limit a Holder’s right to pursue any other remedies available to it hereunder, at law or in
equity including, without limitation, a decree of specific performance and/or injunctive relief with respect to the Company’s failure
to timely deliver shares of Common Stock upon exercise of the Warrant as required pursuant to the terms hereof.

 

    	-6-

     

    

 

v.
No Fractional Shares or Scrip. No fractional shares or scrip representing fractional shares shall be issued upon the exercise
of this Warrant. As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise, the Company
shall, at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied
by the Exercise Price or round up to the next whole share.

 

vi.
Charges, Taxes and Expenses. Issuance of Warrant Shares shall be made without charge to the Holder for any issue or transfer tax
or other incidental expense in respect of the issuance of such Warrant Shares, all of which taxes and expenses shall be paid by the Company,
and such Warrant Shares shall be issued in the name of the Holder or in such name or names as may be directed by the Holder; provided,
however, that in the event that Warrant Shares are to be issued in a name other than the name of the Holder, this Warrant when
surrendered for exercise shall be accompanied by the assignment form attached hereto as Annex B (the “Assignment Form”)
duly executed by the Holder and the Company may require, as a condition thereto, the payment of a sum sufficient to reimburse it for
any transfer tax incidental thereto. The Company shall pay all Transfer Agent fees required for same-day processing of any Notice of
Exercise and all fees to the Depository Trust Company (or another established clearing corporation performing similar functions) required
for same-day electronic delivery of the Warrant Shares.

 

vii.
Closing of Books. The Company will not close its stockholder books or records in any manner which prevents the timely exercise
of this Warrant, pursuant to the terms hereof.

 

    	-7-

     

    

 

e)
Beneficial Ownership Limitations. The Company shall not effect any exercise of this Warrant, and a Holder shall not have the right
to exercise any portion of this Warrant, pursuant to Section 2 or otherwise, to the extent that after giving effect to such issuance
after exercise as set forth on the applicable Notice of Exercise, the Holder (together with the Holder’s Affiliates, and any other
Persons acting as a group together with the Holder or any of the Holder’s Affiliates (such Persons, “Attribution Parties”)),
would beneficially own in excess of the Beneficial Ownership Limitation (as defined below). For purposes of the foregoing sentence, the
number of shares of Common Stock beneficially owned by the Holder and its Affiliates and Attribution Parties shall include the number
of shares of Common Stock issuable upon exercise of this Warrant with respect to which such determination is being made, but shall exclude
the number of shares of Common Stock which would be issuable upon (i) exercise of the remaining, nonexercised portion of this Warrant
beneficially owned by the Holder or any of its Affiliates or Attribution Parties and (ii) exercise or conversion of the unexercised or
nonconverted portion of any other securities of the Company (including, without limitation, any other Common Stock Equivalents) subject
to a limitation on conversion or exercise analogous to the limitation contained herein beneficially owned by the Holder or any of its
Affiliates or Attribution Parties. Except as set forth in the preceding sentence, for purposes of this Section 2(e), beneficial ownership
shall be calculated in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder, it being
acknowledged by the Holder that the Company is not representing to the Holder that such calculation is in compliance with Section 13(d)
of the Exchange Act and the Holder is solely responsible for any schedules required to be filed in accordance therewith and the calculations
required under this Section 2(e). To the extent that the limitation contained in this Section 2(e) applies, the determination of whether
this Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates and Attribution Parties)
and of which portion of this Warrant is exercisable shall be in the sole discretion of the Holder, and the submission of a Notice of
Exercise shall be deemed to be the Holder’s determination of whether this Warrant is exercisable (in relation to other securities
owned by the Holder together with any Affiliates and Attribution Parties) and of which portion of this Warrant is exercisable, in each
case subject to the Beneficial Ownership Limitation, and the Company shall have no obligation to verify or confirm the accuracy of such
determination. In addition, a determination as to any group status as contemplated above shall be determined in accordance with Section
13(d) of the Exchange Act and the rules and regulations promulgated thereunder. For purposes of this Section 2(e), in determining the
number of outstanding shares of Common Stock, a Holder may rely on the number of outstanding shares of Common Stock as reflected in (A)
the Company’s most recent periodic or annual report filed with the Commission, as the case may be, (B) a more recent public announcement
by the Company or (C) a more recent written notice by the Company or the Transfer Agent setting forth the number of shares of Common
Stock outstanding. Upon the written or oral request of a Holder, the Company shall within one (1) Trading Day confirm orally and in writing
to the Holder the number of shares of Common Stock then outstanding. In any case, the number of outstanding shares of Common Stock shall
be determined after giving effect to the conversion or exercise of securities of the Company, including this Warrant, by the Holder or
its Affiliates or Attribution Parties since the date as of which such number of outstanding shares of Common Stock was reported. The
“Beneficial Ownership Limitation” shall be [4.99%]/[9.99%] of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock
issuable upon exercise of this Warrant. The Holder, upon notice to the Company, may increase or decrease the Beneficial Ownership Limitation
provisions of this Section 2(e), provided that the Beneficial Ownership Limitation in no event exceeds 9.99% of the number of shares
of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock upon exercise of this Warrant
held by the Holder and the provisions of this Section 2(e) shall continue to apply. Any increase in the Beneficial Ownership Limitation
will not be effective until the 61st day after such notice is delivered to the Company. The provisions of this Section 2(e)
shall be construed and implemented in a manner otherwise than in strict conformity with the terms of this Section 2(e) to correct this
Section 2(e) (or any portion hereof) which may be defective or inconsistent with the intended Beneficial Ownership Limitation herein
contained or to make changes or supplements necessary or desirable to properly give effect to such limitation. The limitations contained
in this Section 2(e) shall apply to a successor holder of this Warrant.

 

    	-8-

     

    

 

Section
3. Certain Adjustments.

 

a)
Stock Dividends and Splits. If the Company, at any time while this Warrant is outstanding: (i) pays a stock dividend or otherwise
makes a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities payable in shares
of Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Company upon exercise of this
Warrant), (ii) subdivides outstanding shares of Common Stock into a larger number of shares, (iii) combines (including by way of reverse
stock split) outstanding shares of Common Stock into a smaller number of shares, or (iv) issues by reclassification of shares of the
Common Stock any shares of capital stock of the Company, then in each case the Exercise Price shall be multiplied by a fraction of which
the numerator shall be the number of shares of Common Stock (excluding treasury shares, if any) outstanding immediately before such event
and of which the denominator shall be the number of shares of Common Stock outstanding immediately after such event, and the number of
shares issuable upon exercise of this Warrant shall be proportionately adjusted such that the aggregate Exercise Price of this Warrant
shall remain unchanged. Any adjustment made pursuant to this Section 3(a) shall become effective immediately after the record date for
the determination of stockholders entitled to receive such dividend or distribution and shall become effective immediately after the
effective date in the case of a subdivision, combination or re-classification.

 

b)
Subsequent Rights Offerings. In addition to any adjustments pursuant to Section 3(a) above, if at any time while this Warrant
is outstanding the Company grants, issues or sells any Common Stock Equivalents or rights to purchase stock, warrants, securities or
other property pro rata to the record holders of any class of shares of Common Stock (the “Purchase Rights”), then
the Holder will be entitled to acquire, upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder
could have acquired if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without
regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the
date on which a record is taken for the grant, issuance or sale of such Purchase Rights, or, if no such record is taken, the date as
of which the record holders of shares of Common Stock are to be determined for the grant, issue or sale of such Purchase Rights (provided,
however, that to the extent that the Holder’s right to participate in any such Purchase Right would result in the Holder
exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Purchase Right to such extent
(or beneficial ownership of such shares of Common Stock as a result of such Purchase Right to such extent) and such Purchase Right to
such extent shall be held in abeyance for the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding
the Beneficial Ownership Limitation); provided, that such Purchase Right shall terminate on, and shall not be held in abeyance for any
period subsequent to the Termination Date.

 

    	-9-

     

    

 

c)
Pro Rata Distributions. During such time as this Warrant is outstanding, if the Company shall declare or make any dividend or
other distribution of its assets (or rights to acquire its assets) to holders of shares of Common Stock, by way of return of capital
or otherwise (including, without limitation, any distribution of cash, stock or other securities, property or options by way of a dividend,
spin off, reclassification, corporate rearrangement, scheme of arrangement or other similar transaction) (a “Distribution”),
at any time after the issuance of this Warrant, then, in each such case, the Holder shall be entitled to participate in such Distribution
to the same extent that the Holder would have participated therein if the Holder had held the number of shares of Common Stock acquirable
upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial
Ownership Limitation) immediately before the date of which a record is taken for such Distribution, or, if no such record is taken, the
date as of which the record holders of shares of Common Stock are to be determined for the participation in such Distribution (provided,
however, that to the extent that the Holder’s right to participate in any such Distribution would result in the Holder exceeding
the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Distribution to such extent (or in
the beneficial ownership of any shares of Common Stock as a result of such Distribution to such extent) and the portion of such Distribution
shall be held in abeyance for the benefit of the Holder until such time, if ever, as its right thereto would not result in the Holder
exceeding the Beneficial Ownership Limitation); provided, that such Purchase Right shall terminate on, and shall not be held in abeyance
for any period subsequent to the Termination Date.

 

    	-10-

     

    

 

d)
Fundamental Transaction. If, at any time while this Warrant is outstanding, (i) the Company (and all of its Subsidiaries, taken
as a whole), directly or indirectly, in one or more related transactions effects any merger or consolidation of the Company with or into
another Person (other than for the purpose of changing the Company’s name and/or the jurisdiction of incorporation of the Company
or a holding company for the Company), (ii) the Company, directly or indirectly, effects any sale, lease, license, assignment, transfer,
conveyance or other disposition of all or substantially all of its assets in one or a series of related transactions, (iii) any, direct
or indirect, purchase offer, tender offer or exchange offer (whether by the Company or another Person) is completed pursuant to which
holders of Common Stock are permitted to sell, tender or exchange their shares for other securities, cash or property and has been accepted
by the holders of 50% or more of the outstanding shares of Common Stock, (iv) the Company, directly or indirectly, in one or more related
transactions effects any reclassification, reorganization or recapitalization of the Common Stock or any compulsory share exchange pursuant
to which the Common Stock is effectively converted into or exchanged for other securities, cash or property, or (v) the Company, directly
or indirectly, in one or more related transactions consummates a stock or share purchase agreement or other business combination (including,
without limitation, a reorganization, recapitalization, spin-off, merger or scheme of arrangement) with another Person or group of Persons
whereby such other Person or group acquires securities representing more than 50% of the aggregate voting power, including the power
to vote on the election of directors of the Company, of the issued and outstanding equity securities of the Company (each a “Fundamental
Transaction”), then, upon any subsequent exercise of this Warrant, the Holder shall have the right to receive, for each Warrant
Share that would have been issuable upon such exercise immediately prior to the occurrence of such Fundamental Transaction, at the option
of the Holder (without regard to any limitation in Section 2(e) on the exercise of this Warrant), the number of shares of Common Stock
of the successor or acquiring corporation or of the Company, if it is the surviving corporation, and any additional consideration (the
“Alternate Consideration”) receivable as a result of such Fundamental Transaction by a holder of the number of shares
of Common Stock for which this Warrant is exercisable immediately prior to such Fundamental Transaction (without regard to any limitation
in Section 2(e) on the exercise of this Warrant). For purposes of any such exercise, the determination of the Exercise Price shall be
appropriately adjusted to apply to such Alternate Consideration based on the amount of Alternate Consideration issuable in respect of
one share of Common Stock in such Fundamental Transaction, and the Company shall apportion the Exercise Price among the Alternate Consideration
in a reasonable manner reflecting the relative value of any different components of the Alternate Consideration. If holders of Common
Stock are given any choice as to the securities, cash or property to be received in a Fundamental Transaction, then the Holder shall
be given the same choice as to the Alternate Consideration it receives upon any exercise of this Warrant following such Fundamental Transaction.
The Company shall require any successor entity in a Fundamental Transaction in which the Company is not the survivor (the “Successor
Entity”) to assume in writing all of the obligations of the Company under this Warrant and the other Transaction Documents
in accordance with the provisions of this Section 3(d) pursuant to written agreements in form and substance reasonably satisfactory to
the Holder and approved by the Holder (without unreasonable delay) prior to such Fundamental Transaction and shall, at the option of
the Holder, deliver to the Holder in exchange for this Warrant a security of the Successor Entity evidenced by a written instrument substantially
similar in form and substance to this Warrant which is exercisable for a corresponding number of shares of capital stock of such Successor
Entity (or its parent entity) equivalent to the shares of Common Stock acquirable and receivable upon exercise of this Warrant (without
regard to any limitations on the exercise of this Warrant) prior to such Fundamental Transaction, and with an exercise price which applies
the exercise price hereunder to such shares of capital stock (but taking into account the relative value of the shares of Common Stock
pursuant to such Fundamental Transaction and the value of such shares of capital stock, such number of shares of capital stock and such
exercise price being for the purpose of protecting the economic value of this Warrant immediately prior to the consummation of such Fundamental
Transaction), and which is reasonably satisfactory in form and substance to the Holder. Upon the occurrence of any such Fundamental Transaction,
the Successor Entity shall succeed to, and be substituted for (so that from and after the date of such Fundamental Transaction, the provisions
of this Warrant and the other Transaction Documents referring to the “Company” shall refer instead to the Successor Entity),
and may exercise every right and power of the Company and shall assume all of the obligations of the Company under this Warrant and the
other Transaction Documents with the same effect as if such Successor Entity had been named as the Company herein.

 

    	-11-

     

    

 

e)
Calculations. All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of a share, as the
case may be. For purposes of this Section 3, the number of shares of Common Stock deemed to be issued and outstanding as of a given date
shall be the sum of the number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding.

 

f)
Notice to Holder.

 

i.
Adjustment to Exercise Price. Whenever the Exercise Price is adjusted pursuant to any provision of this Section 3, the Company
shall promptly deliver to the Holder by email a notice setting forth the Exercise Price after such adjustment and any resulting adjustment
to the number of Warrant Shares and setting forth a brief statement of the facts requiring such adjustment.

 

ii.
Notice to Allow Exercise by Holder. If (A) the Company shall declare a dividend (or any other distribution in whatever form) on
the Common Stock, (B) the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock, (C) the
Company shall authorize the granting to all holders of the Common Stock rights or warrants to subscribe for or purchase any shares of
capital stock of any class or of any rights, (D) the approval of any stockholders of the Company shall be required in connection with
any reclassification of the Common Stock, any consolidation or merger to which the Company (and all of its Subsidiaries, taken as a whole)
is a party, any sale or transfer of all or substantially all of the assets of the Company, or any compulsory share exchange whereby the
Common Stock is converted into other securities, cash or property, or (E) the Company shall authorize the voluntary or involuntary dissolution,
liquidation or winding up of the affairs of the Company, then, in each case, the Company shall cause to be delivered by email to the
Holder at its last email or other address as it shall appear upon the Warrant Register of the Company, at least 20 calendar days prior
to the applicable record or effective date hereinafter specified, a notice stating (x) the date on which a record is to be taken for
the purpose of such dividend, distribution, redemption, rights or warrants, or if a record is not to be taken, the date as of which the
holders of the Common Stock of record to be entitled to such dividend, distributions, redemption, rights or warrants are to be determined
or (y) the date on which such reclassification, consolidation, merger, sale, transfer or share exchange is expected to become effective
or close, and the date as of which it is expected that holders of the Common Stock of record shall be entitled to exchange their shares
of the Common Stock for securities, cash or other property deliverable upon such reclassification, consolidation, merger, sale, transfer
or share exchange; provided that the failure to deliver such notice or any defect therein or in the delivery thereof shall not affect
the validity of the corporate action required to be specified in such notice. To the extent that any notice provided in this Warrant
constitutes, or contains, material, non-public information regarding the Company or any of the Subsidiaries, the Company shall simultaneously
file such notice with the Commission pursuant to a Current Report on Form 8-K. The Holder shall remain entitled to exercise this Warrant
during the period commencing on the date of such notice to the effective date of the event triggering such notice except as may otherwise
be expressly set forth herein.

 

    	-12-

     

    

 

Section
4. Transfer of Warrant.

 

a)
Transferability. This Warrant and all rights hereunder (including, without limitation, any registration rights) are transferable,
in whole or in part, upon surrender of this Warrant at the principal office of the Company or its designated agent, together with a written
assignment of this Warrant substantially in the form attached hereto duly executed by the Holder or its agent or attorney and funds sufficient
to pay any transfer taxes payable upon the making of such transfer. Upon such surrender and, if required, such payment, the Company shall
execute and deliver a new Warrant or Warrants in the name of the assignee or assignees, as applicable, and in the denomination or denominations
specified in such instrument of assignment, and shall issue to the assignor a new Warrant evidencing the portion of this Warrant not
so assigned, and this Warrant shall promptly be cancelled. Notwithstanding anything herein to the contrary, the Holder shall not be required
to physically surrender this Warrant to the Company unless the Holder has assigned this Warrant in full, in which case, the Holder shall
surrender this Warrant to the Company within three (3) Trading Days of the date on which the Holder delivers a duly executed Assignment
Form to the Company assigning this Warrant in full. The Warrant, if properly assigned in accordance herewith, may be exercised by a new
holder for the purchase of Warrant Shares without having a new Warrant issued.

 

b)
New Warrants. This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid office of
the Company, together with a written notice specifying the names and denominations in which new Warrants are to be issued, signed by
the Holder or its agent or attorney. Subject to compliance with Section 4(a), as to any transfer which may be involved in such division
or combination, the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants to be divided
or combined in accordance with such notice. All Warrants issued on transfers or exchanges shall be dated the initial issuance date of
this Warrant and shall be identical with this Warrant except as to the number of Warrant Shares issuable pursuant thereto.

 

c)
Warrant Register. The Company shall register this Warrant, upon records to be maintained by the Company for that purpose (the
“Warrant Register”), in the name of the record Holder hereof from time to time. The Company may deem and treat the
registered Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder,
and for all other purposes, absent actual notice to the contrary.

 

Section
5. Miscellaneous.

 

a)
No Rights as Stockholder Until Exercise; No Settlement in Cash. This Warrant does not entitle the Holder to any voting rights,
dividends or other rights as a stockholder of the Company prior to the exercise hereof as set forth in Section 2(d)(i), except as expressly
set forth in Section 3. Without limiting any rights of a Holder to receive Warrant Shares on a “cashless exercise” pursuant
to Section 2(c) or to receive cash payments pursuant to Section 2(d)(i) and Section 2(d)(iv) herein, in no event shall the Company be
required to net cash settle an exercise of this Warrant.

 

    	-13-

     

    

 

b)
Loss, Theft, Destruction or Mutilation of Warrant. The Company covenants that upon receipt by the Company of evidence reasonably
satisfactory to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant Shares,
and in case of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case of the Warrant,
shall not include the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate, if mutilated, the
Company will make and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation, in lieu of such Warrant
or stock certificate.

 

c)
Saturdays, Sundays, Holidays, etc. If the last or appointed day for the taking of any action or the expiration of any right required
or granted herein shall not be a Trading Day, then such action may be taken or such right may be exercised on the next succeeding Trading
Day.

 

d)
Authorized Shares.

 

The
Company covenants that during the period the Warrant is outstanding, it will reserve from its authorized and unissued Common Stock a
sufficient number of shares to provide for the issuance of the Warrant Shares upon the exercise of any purchase rights under this Warrant.
The Company further covenants that its issuance of this Warrant shall constitute full authority to its officers who are charged with
the duty of issuing the necessary Warrant Shares upon the exercise of the purchase rights under this Warrant. The Company will take such
reasonable action as may be necessary to assure that such Warrant Shares may be issued as provided herein without violation of any applicable
law or regulation, or of any requirements of the Trading Market upon which the Common Stock may be listed. The Company covenants that
all Warrant Shares which may be issued upon the exercise of the purchase rights represented by this Warrant will, upon exercise of the
purchase rights represented by this Warrant and payment for such Warrant Shares in accordance herewith, be duly authorized, validly issued,
fully paid and nonassessable and free from all taxes, liens and charges created by the Company in respect of the issue thereof (other
than taxes in respect of any transfer occurring contemporaneously with such issue).

 

Except
and to the extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending
its certificate of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale
of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant,
but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary
or appropriate to protect the rights of Holder as set forth in this Warrant against impairment. Without limiting the generality of the
foregoing, the Company will (i) not increase the par value of any Warrant Shares above the amount payable therefor upon such exercise
immediately prior to such increase in par value, (ii) take such action as may be necessary or appropriate in order that the Company may
validly and legally issue fully paid and nonassessable Warrant Shares upon the exercise of this Warrant and (iii) use commercially reasonable
efforts to obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof, as may
be, necessary to enable the Company to perform its obligations under this Warrant.

 

    	-14-

     

    

 

Before
taking any action which would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or in the
Exercise Price, the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from
any public regulatory body or bodies having jurisdiction thereof.

 

e)
Jurisdiction. All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall be governed
by and construed and enforced in accordance with the internal laws of the State of New York, without regard to the principles of conflicts
of law thereof. The Company and, by accepting this Warrant, the Holder each agrees that all legal proceedings concerning the interpretations,
enforcement and defense of the transactions contemplated by this Warrant (whether brought against the Company or the Holder or their
respective affiliates, directors, officers, shareholders, partners, members, employees or agents) shall be commenced exclusively in the
state and federal courts sitting in the City of New York. The Company and, by accepting this Warrant, the Holder each hereby irrevocably
submits to the exclusive jurisdiction of the state and federal courts sitting in the City of New York, Borough of Manhattan for the adjudication
of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein, and hereby irrevocably
waives, and agrees not to assert in any suit, action or proceeding, any claim that it is not personally subject to the jurisdiction of
any such court, that such suit, action or proceeding is improper or is an inconvenient venue for such proceeding. The Company and, by
accepting this Warrant, the Holder each hereby irrevocably waives personal service of process and consents to process being served in
any such suit, action or proceeding by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of
delivery) to such party at the address in effect for notices to it under this Warrant and agrees that such service shall constitute good and
sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process
in any other manner permitted by law. If the Company or the Holder shall commence an action, suit or proceeding to enforce any provisions
of this Warrant, the prevailing party in such action, suit or proceeding shall be reimbursed by the other party for their reasonable
attorneys’ fees and other costs and expenses incurred with the investigation, preparation and prosecution of such action or proceeding.

 

f)
Restrictions. The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered, and
the Holder does not utilize cashless exercise, will have restrictions upon resale imposed by state and federal securities laws.

 

g)
Nonwaiver and Expenses. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder shall
operate as a waiver of such right or otherwise prejudice the Holder’s rights, powers or remedies. Without limiting any other provision
of this Warrant, if the Company willfully and knowingly fails to comply with any provision of this Warrant, which results in any material
damages to the Holder, the Company shall pay to the Holder such amounts as shall be sufficient to cover any costs and expenses including,
but not limited to, reasonable attorneys’ fees, including those of appellate proceedings, incurred by the Holder in collecting
any amounts due pursuant hereto or in otherwise enforcing any of its rights, powers or remedies hereunder.

 

    	-15-

     

    

 

h)
Notices. Any and all notices or other communications or deliveries to be provided by the Holder hereunder including, without limitation,
any Notice of Exercise, shall be in writing and delivered personally, by email or sent by a nationally recognized overnight courier service,
addressed to the Company, at 7946 Ivanhoe Avenue, Suite 201, La Jolla, California 92037,
Attention: David Humphrey, CFO, email address: dhumphrey@ensysce.com, or such other email address or address as the Company may specify
for such purposes by notice to the Holder. Any and all notices or other communications or deliveries to be provided by the Company hereunder
shall be in writing and delivered personally, by email, or sent by a nationally recognized overnight courier service addressed to the
Holder at the email address or address of the Holder appearing on the books of the Company. Any notice or other communication or deliveries
hereunder shall be deemed given and effective on the earliest of (i) the time of transmission, if such notice or communication is delivered
via email at the email address set forth in this Section prior to 5:30 p.m. (New York City time) on any date, (ii) the next Trading Day
after the time of transmission, if such notice or communication is delivered via email at the email address set forth in this Section
on a day that is not a Trading Day or later than 5:30 p.m. (New York City time) on any Trading Day, (iii) the second Trading Day following
the date of mailing, if sent by U.S. nationally recognized overnight courier service, or (iv) upon actual receipt by the party to whom
such notice is required to be given. To the extent that any notice provided by the Company hereunder constitutes, or contains, material,
non-public information regarding the Company or any subsidiaries, the Company shall simultaneously file such notice with the Commission
pursuant to a Current Report on Form 8-K.

 

i)
Limitation of Liability. No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant
to purchase Warrant Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability of
the Holder for the purchase price of any Common Stock or as a stockholder of the Company, whether such liability is asserted by the Company
or by creditors of the Company.

 

j)
Remedies. The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages, will
be entitled to specific performance of its rights under this Warrant. The Company agrees that monetary damages would not be adequate
compensation for any loss incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to
assert the defense in any action for specific performance that a remedy at law would be adequate.

 

    	-16-

     

    

 

k)
Successors and Assigns. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby shall
inure to the benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted assigns
of Holder. The provisions of this Warrant are intended to be for the benefit of any Holder from time to time of this Warrant and shall
be enforceable by such Holder.

 

l)
Amendment. This Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company and
the holders of at least a majority of the Common Stock issuable upon the exercise of the then outstanding Warrants (determined without
giving effect to Section 2(e) of the Warrants); provided such modification, amendment or waiver applies to all of the then outstanding
Warrants.

 

m)
Severability. Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and valid
under applicable law, but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall
be ineffective to the extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining
provisions of this Warrant.

 

n)
Headings. The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed
a part of this Warrant.

 

o)
Electronic Signatures. Electronically scanned and transmitted signatures, including by email attachment, shall be deemed originals
for all purposes of this Warrant.

 

********************

 

(Signature
Page Follows)

 

    	-17-

     

    

 

IN
WITNESS WHEREOF, the Company has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first above
indicated.

 

	 	ENSYSCE BIOSCIENCES, INC. 
	 	 	 
	 	By:	 
	 	Name:	Dr.
    Lynn Kirkpatrick
	 	Title:	President
    and Chief Executive Officer

 

    	-18-

     

    

 

Annex
A

 

NOTICE
OF EXERCISE

 

	To:	ENSYSCE
    BIOSCIENCES, INC.

 

(1)
The undersigned hereby elects to purchase ________ Warrant Shares of the Company pursuant to the terms of the attached Warrant (only
if exercised in full), and tenders herewith payment of the exercise price in full, together with all applicable transfer taxes, if any.

 

(2)
Payment shall take the form of (check applicable box):

 

[
] in lawful money of the United States; or

 

[
] if permitted the cancellation of such number of Warrant Shares as is necessary, in accordance with the formula set forth in subsection
2(c), to exercise this Warrant with respect to the maximum number of Warrant Shares purchasable pursuant to the cashless exercise procedure
set forth in subsection 2(c).

 

(3)
Please issue said Warrant Shares in the name of the undersigned or in such other name as is specified below:

 

	 	 	 

 

The
Warrant Shares shall be delivered to the following DWAC Account Number:

 

	 	 	 
	 	 	 
	 	 	 

 

[SIGNATURE
OF HOLDER]

 

Name
of Investing Entity: ___________________________________________________________________________

Signature
of Authorized Signatory of Investing Entity: _____________________________________________________

Name
of Authorized Signatory: _______________________________________________________________________

Title
of Authorized Signatory: ________________________________________________________________________

Date:
___________________________________________________________________________________________

 

    	 

     

    

 

Annex
B

 

ASSIGNMENT
FORM

 

(To
assign the foregoing Warrant, execute this form and supply required information. Do not use this form to exercise the Warrant to purchase
shares.)

 

FOR
VALUE RECEIVED, the foregoing Warrant and all rights evidenced thereby are hereby assigned to

 

	Name:	 
	 	(Please
    Print)
	 	 
	Address:	 
	 	(Please
    Print)
	 	 
	Phone
    Number:	 
	 	 
	Email
    Address:	 
	 	 
	Dated:
    _______________ __, ______	 
	 	 
	Holder’s
    Signature:________________________________	 
	 	 
	Holder’s
    Address:_________________________________Exhibit
10.1

 

Scripps
Safe, Inc. 

 

EMPLOYMENT
AGREEMENT

 

This
EMPLOYMENT AGREEMENT (this “Agreement”) is entered into effective April 1, 2022 (the “Effective
Date”), by Jacqueline Von Zwehl (“Executive”) and Scripps Safe, Inc. (the “Company”,
together with Executive, the “Parties”).

 

RECITALS

 

A.
Company desires to hire Executive as Chief Executive Officer to compensate Executive for Executive’s services to the Company; and

 

B.
Executive wishes to be employed by the Company and provide services to the Company in return for certain compensation; and

 

C.
Company and Executive desire to enter into this Agreement

 

Accordingly,
in consideration of the mutual promises and covenants contained in this Agreement and for other good and valuable consideration, the
sufficiency of which is acknowledged, the parties agree to the following:

 

1.
DEFINITIONS. 

 

1.1
“Affiliates” means, with respect to a Party, any entity which, directly or indirectly, is controlled by
or is under common control with such Party.

 

1.2
“Board of Directors” or “Board” means the Board of Directors of the Company.

 

1.3
“Florida Office Location” means the current location of the Company’s offices in Naples, Florida,
or such other location the Company may elect to relocate such offices.

 

1.4
“Cause” will be limited to mean the following:

 

(i)
Willful misfeasance or nonfeasance by Executive that materially injures the reputation, business or business relationships of the
Company or its Affiliates, or any of their respective officers, directors or employees and such action or failure is not remedied or
reasonable steps to affect such remedy are not commenced within thirty (30) days following receipt of written notice;

 

(ii)
Any act involving moral turpitude or conviction of a crime that reflects in some material fashion unfavorably upon the business or
business relationships of the Company, its Affiliates, or any of its officers, directors or employees;

 

(iii)
The willful and continued failure to perform substantially the Executive’s duties or to follow the reasonable direction of
the principal executive within thirty (30) business days after receipt by Executive of written notice of such failure, other than by
reason of Disability (as defined below) or approved leave of absence; or

 

(iv)
Willful and prolonged absence from work by Executive, other than by reason of Disability, approved leave of absence, or otherwise
in compliance with Company Policies, whether paid or unpaid.

 

1.5
“Code” will mean the Internal Revenue Code of 1986, as amended from time to time, and the regulations promulgated
thereunder.

 

1.6
“Company Policies” will mean all policies and procedures of the Company and its Affiliates that are applicable
to employees of the Company as they may be adopted, revised or deleted from time to time in the sole discretion of the Company or its
Affiliates, as the case may be, in whatever form such policies and procedures (including all revisions and updates thereto) are made
available to Executive after notification of such availability.

 

    	 

     

    

 

1.7
“Disability” will mean the earliest of the date on which Executive is deemed disabled under: (i) the long-term
disability policy maintained by the Company; (ii) Code Section 22(e)(3); or (iii) the determination of the Social Security Administration.
Notwithstanding the foregoing, Executive will not be considered to have suffered a Disability under subparagraph (ii) above if Executive
timely provides medical certification from a qualified licensed physician that Executive is able to perform the essential functions of
Executive’s position, with or without reasonable accommodation.

 

1.8
“Good Reason” will mean the occurrence of any of the following without Executive’s prior written
consent:

 

(i)
the removal of Executive as Chief Executive Officer of the Company, assignment to Executive of any duties or responsibilities materially
inconsistent with Executive’s position, including any material diminution of Executive’s status, title, authority, duties
or responsibilities or any other action that results in a material diminution in such status, title, authority, duties or responsibilities;

 

(ii)
the reduction by five percent (5%) or more of Executive’s base salary or the reduction by five percent (5%) or more of the
aggregate of Executive’s base salary and Incentive Compensation target cumulatively during any one year period, without Executive’s
consent, or any action that materially adversely affects Executive’s overall compensation and benefits package, provided that the
Company may change the benefits package if those changes are made on a non-discriminatory basis for all employees who participate in
the benefits plans available to Executive;

 

(iii)
the failure of the Company to pay to Executive any portion or installment of any salary, Incentive Compensation or deferred compensation
within thirty (30) days of the date such compensation is due; or

 

(iv)
requiring Executive perform her duties at a location outside of the Florida Office Location.

 

1.9
“Restricted Business” will mean the business of Business of the Company existing as of the Termination
Date, which as of the date of this Agreement means the business of providing security and storage solutions for the pharmaceutical, healthcare,
and drug industries.

 

1.9
“Termination Date” will mean Executive’s last day of employment, regardless of whether termination is on
account of death, Disability, with or without Cause, or a resignation with or without Good Reason.

 

2.
EMPLOYMENT BY THE COMPANY. 

 

2.1
POSITION. Subject to the terms set forth in this Agreement, the Company agrees to employ Executive in the position of Chief Executive
Officer and Executive hereby accepts such employment and position. During the term of Executive’s employment with the Company,
Executive will devote Executive’s best efforts and substantially all of Executive’s business time and attention to the business
of the Company.

 

2.2
Duties. Executive will report to the Board of Directors of the Company and will perform
such duties as are normally associated with Executive’s position as are assigned to Executive from time to time. Executive will
perform Executive’s duties under this Agreement at the Company’s Florida Office Location.

 

2.3
TERM. The term of this Agreement will run from the Effective Date until such time as it is terminated in accordance with the terms
of this Agreement.

 

2.4
COMPANY POLICIES AND BENEFITS. The employment relationship between the parties will be subject to the Company Policies. Subject to
any specific exceptions or conditions set forth in Section 3.3, Executive will be eligible to participate on substantially the same basis
as similarly situated Executives in the Company’s benefit plans and programs in effect from time to time during Executive’s
employment; provided, however, that participation and awards under any equity compensation or equity Incentive Compensation plan
or program will be determined by the Board of Directors on an individual, case-by-case basis. All matters of eligibility for coverage
or benefits under any benefit plan or program will be determined in accordance with the provisions of such plan or program. The Company
reserves the right to change, alter, or terminate any benefit plan or program in its sole discretion; provided, however,
that no such change, alteration or termination will change any vested or accrued benefits or rights of Executive. Notwithstanding the
foregoing, in the event that the terms of this Agreement expressly provide Executive with benefits that differ from the Company’s
generally available benefits, then the terms of this Agreement will control.

 

    	 

     

    

 

3.
COMPENSATION AND BENEFITS.

 

3.1
SALARY. Executive will receive for Executive’s services to be rendered under this Agreement an initial annualized base salary
of $180,000 (the “Base Salary”). Upon the company’s IPO on the NASDAQ, Executive’s annualized base
salary will be increased to $325,000, subject to bi-annual review and adjustment from time to time by the Company. The Base Salary will
be payable in accordance with Company’s standard payroll practices.

 

(a)
Annual Bonus. Executive shall be eligible to earn annual bonus compensation based on the achievement of certain goals and
performance criteria established by the Board. The Company agrees that Executive’s target annual bonus for fiscal year(s) 2022-2025
will be minimum of 20% of the current Base Salary with a maximum payout of up to 150% based on target achievement.

 

(b)
Equity Incentive.

 

(1)
Initial Grant. Executive is eligible to participate in the Company’s Incentive Stock Plan, subject to Board approval.
Executive is eligible to receive equity bonuses and stock options.

 

3.2
EXPENSE REIMBURSEMENT. The Company will reimburse Executive for reasonable business expenses incurred by Executive during the period
Executive is employed by the Company, in accordance with the Company’s standard expense reimbursement policy.

 

3.3
PAID TIME OFF. Executive is entitled to five weeks’ paid vacation during each calendar year. If Executive does not take the
full vacation available in any year, the unused vacation may be carried over to the next calendar year, and Executive will be compensated
for it.

 

3.4
BENEFITS. As provided in Section 2.4, Executive will receive benefits in accordance with the Company’s standard benefits plan
and policies, as amended from time to time.

 

4.
NON-COMPETITION; NON-SOLICITATION; CONFIDENTIALITY. 

 

4.1
NON-COMPETITION. Executive acknowledges that Executive will gain extensive and valuable experiences and knowledge in the business
conducted by the Company and its Affiliates and will have extensive contacts with customers of the Company and its Affiliates. Accordingly,
in consideration of the mutual promises contained in this Agreement, Executive covenants and agrees with the Company that, during the
term of this Agreement and for the Applicable Severance Payout Period (as defined in Section 7.2(c)) following the Executive’s
Termination Date, Executive will not compete directly or indirectly with the Company or its Affiliates. Competing directly or indirectly
with the Company and its Affiliates will mean engaging or having a material interest, directly or indirectly, as owner, employee, officer,
director, partner, venturer, stockholder, capital investor, consultant, agent, principal, advisor or otherwise, either alone or in association
with others, in the operation of any entity’s division or group which engages in the Restricted Business. Competing directly or
indirectly with the Company or its Affiliates, as used in this Agreement, will not include having an ownership interest as an inactive
investor, which for purposes of this Agreement will mean the beneficial ownership of less than five percent (5%) of the outstanding shares
of any series or class of securities of any competitor of the Company, which shares are publicly traded in the securities markets. This
Section 4.1 will cease to apply in the event the Company is in breach of any obligations to provide severance benefits in accordance
with Section 7.2 and fails to cure such breach within twenty (20) days of receiving written notice of such breach from Executive. Executive
agrees that any violation of this Section 4.1 by Executive, as determined by a court of law, will result in termination of the Company’s
obligations to provide severance benefits under this Agreement and in the event of such termination, Executive will be required to repay
to the Company any such severance benefits previously received. 

 

    	 

     

    

 

4.2
NON-SOLICITATION. Executive acknowledges that Executive will have extensive contacts with employees and customers of the Company.
Accordingly, in consideration of the mutual promises contained in this Agreement, Executive covenants and agrees that during the term
of this Agreement, and for the Applicable Severance Payout Period following Executive’s Termination Date, Executive will not (i)
solicit, raid, entice or induce any employee of the Company or its Affiliates to leave the employ of the Company or its Affiliates; (ii)
interfere with the relationship of the Company or its Affiliates with any such employees, including, but not limited to, hiring such
employee (except pursuant to a general solicitation which is not directed specifically to any such employees); or (iii) personally target
or solicit customers of the Company or its Affiliates to purchase products or services in competition with the Company’s or its
Affiliates products or services or to terminate a relationship with the Company or its Affiliates. This Section 4.2 will cease to apply
in the event the Company is in breach of any obligations to provide severance benefits in accordance with Section 7.2 and fails to cure
such breach within twenty (20) days of receiving notice of such breach from Executive. Executive agrees that any violation of this Section
4.2 by Executive, as determined by a court of law, will result in termination of the Company’s obligations to provide severance
benefits hereunder and in the event of such termination, Executive will be required to repay to the Company any such severance benefits
previously received.

 

4.3
CONFIDENTIALITY. Executive acknowledges that Executive will have access to certain information related to the business, operations,
future plans and customers of the Company and its Affiliates, the disclosure or use of which could cause the Company substantial losses
and damages. Accordingly, Executive acknowledges and affirms the terms and conditions of the confidentiality agreement signed by Executive
with the Company on the date hereof in connection with Executive’s employment (the “Confidentiality Agreement”),
which is incorporated by reference. The terms and conditions of Sections 4.1 and 4.2 will take precedence over any non-competition/non-solicitation
provisions contained in the Confidentiality and Non-Compete Agreement

 

4.4
Derogatory Statements. During the term of this Agreement
and for the Applicable Severance Payout Period (as defined in Section 7.2(c)) following the Executive’s Termination Date, each
Party (on behalf of such Party and such Party’s Affiliates) agrees that such Party will not during such period make public statements
in derogation of the other Party or its Affiliates; provided, that, the foregoing covenant regarding making public statements in derogation
of the other Party or its Affiliates shall not restrict such Party from exercising protected rights to the extent that such rights cannot
be waived by agreement or from complying with any applicable law or regulation or a valid order of a court of competent
jurisdiction or an authorized government agency; provided, further, that such compliance does not exceed that required by the law, regulation,
or order and such Party provides prompt written notice of any such order to the other Party.

 

5.
OUTSIDE ACTIVITIES. Except with the prior written consent of the principal executive of the Company, Executive will not, while employed
by the Company, undertake or engage in any other employment, occupation, consulting, advisory, or other business enterprise or business
activities that would interfere with Executive’s responsibilities and the performance of Executive’s duties under this Agreement
with the exception that engaging in charitable, civic, community activities and serving on boards of directors of charitable or civic
organizations will not constitute interference, provided the time spent in such activities does not negatively impact Executive’s
performance of Executive’s duties under this Agreement.

 

6.
NO CONFLICT WITH EXISTING OBLIGATIONS. Executive represents that Executive’s performance of all the terms of this Agreement
and as an executive of the Company does not and will not breach any agreement or obligation of any kind made prior to Executive’s
employment by the Company, including agreements or obligations Executive may have with prior employers or entities for which Executive
has provided services. Executive has not entered into, and Executive agrees that Executive will not enter into, any agreement or obligation,
either written or oral, that conflicts with Executive’s obligations hereunder, it being acknowledged and agreed that Executive
(i) shall not continue to perform any services under any agreement entered into prior to the date hereof without the Company’s
prior written consent and (ii) has delivered true and complete copies of all such agreements to the Company prior to the date hereof.

 

    	 

     

    

 

7.
TERMINATION OF EMPLOYMENT. Executive’s employment under this Agreement shall terminate:

 

(a)
Resignation by Executive. Upon the effective date (if any) of Executive’s resignation;

 

(b)
Termination by the Company for Cause. Immediately upon written notice by the Company to Executive for Cause;

 

(c)
Death. Immediately upon the death of Executive; or

 

(d)
Disability. Upon the date that is 10 days after the Company gives written notice to Executive stating that Executive’s
employment is being terminated on account of Executive’s “Disability” (as defined below).

 

(e)
Definitions. For purposes of this Agreement:

 

(1)
“Cause” will exist if the Company determines that Executive willfully or through gross negligence acted or failed
to act in a manner that materially damages the Company, any Affiliate, its stockholders or the Company’s or any Affiliate’s
financial condition or reputation or involves fraud. Notwithstanding anything in this to the contrary, the failure of the Company or
any Affiliate to achieve budgeted or projected financial or similar performance objectives shall not, in and of itself, be considered
a breach of any obligation under this Agreement or to otherwise constitute “Cause” as defined herein.

 

(2)
“Disability” shall be deemed to exist if Executive is unable, despite reasonable accommodation, to perform the essential
functions of her current position due to physical illness, injury or other medical condition for a period of not less than six (6) full
months in any 12-month period.

 

7.1
STANDARD TERMINATION PAYMENTS.

 

a.
Salary and Reimbursements. Regardless of the reason for termination, the Company will pay Executive on the first regularly scheduled
payroll date following Executive’s Termination Date any Base Salary accrued but unpaid as of Executive’s Termination Date,
the value of any accrued paid time off unused by Executive as of Executive’s Termination Date, and any unpaid Expense Reimbursement,
so long as the Expense Reimbursement complies with the Company guidelines for such requests.

 

7.2
SEVERANCE BENEFITS — TERMINATION WITH CAUSE/RESIGNATION 

 

a.
Company’s Right to Terminate. The Company will have the right to terminate Executive’s employment under this Agreement
for any of the following reasons:

 

(i)
upon Executive’s Disability in accordance with Section 7.3;

 

(ii)
for Cause, by giving notice as described in Section 7.6;

 

b.
Executive’s Right to Terminate. Executive will have the right to resign Executive’s employment with the Company at any
time, as well as following an event constituting Good Reason.

 

c.
Severance Benefits. In the event that the Company terminates Executive’s employment with Cause or Executive resigns for Good
Reason, Executive will receive, in addition to the Standard Termination Payments, the following:

 

(i)
Severance Payments. Provided that Executive delivers to the Company a fully executed and complete release (excluding the release
of any obligations of the Company or its affiliates, or any claims Executive may have without revocation, in favor of the Company and
its Affiliates, and in form and substance satisfactory to the Company (the “Release”) within thirty (30) days
of Executive’s Termination Date (the “Execution Deadline”), the Company will provide to Executive (a)
an amount equal to twelve (12) months of Executive’s then-current Base Salary. The Severance Payments will be payable in equal
installment payments over the twelve (12) month period (“Applicable Severance Payout Period”) starting retroactively
from the Termination Date in accordance with the Company’s regular bi-weekly paydays, or if different, in accordance with the Company’s
customary payroll practices.

 

(ii)
COBRA Benefits. In the event Executive elects continuation coverage pursuant to the Consolidated Omnibus Budget Reconciliation Act
of 1985 (“COBRA”) in accordance with the COBRA materials that will be provided to Executive by the Company or the Company’s
third party COBRA administrator, the Company will pay the Company’s portion (based upon the Company’s monthly premium subsidy
immediately prior to the Termination Date) of Executive’s COBRA premium for the same medical, dental and vision benefit plan coverage
(“Group Health Plan Coverage”) Executive and Executive’s dependents had as of the Termination Date for
the Applicable Severance Payout Period, or until Executive elects to receive group medical, dental and vision insurance from another
source, whichever occurs first. Payment of COBRA premiums (“COBRA Benefits”) will be made by the Company on
Executive’s and Executive’s dependents behalf directly to the Group Health Plan’s COBRA administrator. Executive will
be mailed a COBRA packet at her last known address. Such packet will contain additional information about Executive’s COBRA rights
and responsibilities.

 

    	 

     

    

 

(iii)
Severance Benefits Contingent on Execution of Release. Notwithstanding the foregoing, any Severance Payments that are otherwise payable
before the Execution Deadline will be withheld pending Executive’s execution and delivery of the Release and will be paid on the
payroll date immediately following the Execution Deadline. For the avoidance of doubt, Executive will forfeit the right to receive any
Severance Payments or COBRA Benefits (to the extent such forfeiture of COBRA Benefits is permissible under applicable law) if Executive
fails to deliver the Release by the Execution Deadline. For this forfeiture to take effect, the Release will not materially alter Executive’s
rights to receive any payments or benefits under this Agreement; enlarge Executive’s obligations under this Agreement, including
without limitation, Executive’s covenants of non-competition and non-solicitation; or impose material new obligations on Executive.

 

d.
Compliance with Code Section 409A. The Company and Executive intend that (i) payments under Section 7.2(c)(i) will be made on account
of an involuntary separation from service within the meaning of Treasury Regulation section 1.409A-1(n)(1) or a separation from service
for good reason within the meaning of Treasury Regulation section 1.409A-1(n)(2), (ii) amounts paid under Section 7.2(c)(i) constitute
separation pay exempt from Internal Revenue Code Section 409A under Treasury Regulation section 1.409A-1(b)(9)(iii), and (iii) Payments
under Section 7.2(c)(ii) will be exempt from Code Section 409A as a non-taxable fringe benefit to Executive, but neither party will be
liable to the other in the event any such payment receives different tax treatment. In the event any of these payments is determined
to be deferred compensation subject to Internal Revenue Code Section 409A, the payments will comply with Section 7.7.

 

7.3
TERMINATION UPON DEATH OR DISABILITY OF EXECUTIVE.

 

a.
Upon Executive’s death while employed pursuant to this Agreement, this Agreement will automatically terminate.

 

b.
Subject to applicable state and federal law, the Company will at all times have the right, upon thirty (30) days written notice to
Executive, to terminate this Agreement based on Executive’s Disability.

 

c.
In the event Executive’s employment is terminated due to Executive’s death or Disability, the Company will pay to Executive
or Executive’s heirs or estate all Standard Termination Payments together with any other compensation and benefits payable to Executive
through the Executive’s Termination Date under any compensation or benefit plan, program or arrangement during such period. In
addition, if Executive, or if Executive is deceased, a participant on Executive’s health insurance plan, elects COBRA coverage,
the Company will pay its third party administrator the full cost of COBRA coverage for twelve (12) months from the Executive’s
Termination Date.

 

7.4
Notice; Effective Date of Termination.

 

a.
Termination of Executive’s employment pursuant to this Agreement will be effective on the earliest of:

 

(i)
excluding a termination due to Executive’s death or Disability, the date on which the Company gives notice to Executive of
Executive’s termination, with or without Cause, unless the Company specifies a later date, in which case, termination will be effective
as of such later date;

 

(ii)
the date of Executive’s death;

 

(iii)
ten (10) days after the Company gives notice to Executive of Executive’s termination on account of Executive’s Disability;
or

 

    	 

     

    

 

(iv)
thirty (30) days after Executive gives written notice to the Company of Executive’s resignation, provided that the Company
may set a termination date at any time between the date of notice and the 30th day thereafter (i.e., the effective date of resignation,
but for this Section 7.5(a)), in which case the Executive’s resignation will be effective as of such earlier date (the date on
which Executive’s resignation becomes effective, the “Actual Resignation Effective Date”).

 

b.
In the event that notice of a termination is given orally, at the other party’s request, the party giving notice must provide
written confirmation of such notice within five (5) business days of the request. In the event of a termination for Cause, written confirmation
will specify the subsection(s) of the definition of Cause being relied on by the Company to support the decision to terminate for Cause,
to afford Executive a reasonable opportunity to effect a cure, if permitted and possible under the applicable subsections of the definition
of Cause. In the event of a resignation for Good Reason, written confirmation will specify the subsection(s) of the definition of Good
Reason being relied on by Executive to support the decision to resign for Good Reason, to afford the Company a reasonable opportunity
to cure under the applicable subsections of the definition of Good Reason.

 

7.5
COOPERATION WITH THE COMPANY AFTER TERMINATION OF EMPLOYMENT. Notwithstanding anything to the contrary contained herein, payment
of the amounts specified in this Agreement is conditional upon Executive reasonably cooperating with the Company in connection with all
matters relating to Executive’s employment with the Company, assisting the Company as reasonably requested in transitioning Executive’s
responsibilities to Executive’s replacement, and Executive being available to answer questions and provide transition assistance
to the Company through the end of the period during which Severance Benefits are to be paid. Following Executive’s Termination
Date, such assistance will be provided at mutually acceptable times, and in reasonable amounts, taking into account other commitments
that Executive may have. Executive agrees to use Executive’s best efforts to minimize any conflicts with other commitments to facilitate
this assistance. The Company agrees to reimburse Executive for reasonable out of pocket, pre-approved expenses incurred in providing
such assistance.

 

7.6
APPLICATION OF SECTION 280G. In the event that it is determined that the Severance Benefit payable to Executive pursuant to Section
7 of this Agreement, when added to any other payment or benefit to Executive from the Company that would be considered a “parachute
payment” (a “Parachute Payment”), within the meaning of section 280G of the Code, would cause Executive
to be considered to receive an “excess parachute payment” within the meaning of section 280G of the Code (an “Excess
Parachute Payment”), the amount payable to Executive pursuant to Section 7 of this Agreement will be reduced to the maximum
amount that, when added to any other Parachute Payments made to Executive, could be paid to Executive without causing Executive to receive
an Excess Parachute Payment. Notwithstanding the foregoing, the Severance Benefit payable to Executive pursuant to Section 7 of this
Agreement will not be reduced if (i) the net amount payable to Executive without the reduction described in the preceding sentence, but
reduced by all Federal, state and local income and employment taxes payable by Executive on the Severance Benefit payable pursuant to
this Agreement and all other Parachute Payments plus the excise tax payable on the Excess Parachute Payment pursuant to Section 4999
of the Code, is greater than (ii) the net amount that would be payable to Executive with the reduction described in the preceding sentence
and reduced by all Federal, state and local income and employment taxes payable by Executive on the Severance Benefit payable pursuant
to this Agreement and all other Parachute Payments. For purposes of this Section 7.7, Executive will be deemed to pay Federal income
tax and employment taxes at the highest marginal rate of Federal income and employment taxation in the calendar year in which the Excess
Parachute Payment would occur and state and local income taxes at the highest marginal rate of taxation in the state and locality of
Executive’s residence in the calendar year in which the Excess Parachute Payment would be made, net of the reduction in Federal
income taxes that Executive may obtain from the deduction of such state and local income taxes. In addition, all determinations to be
made under this Section 7.7 will be made by the Company’s independent public accountant (the “Accounting Firm”)
immediately before the date the Severance Benefit under Section 7 is to be paid. The Accounting Firm will provide its determinations
and any supporting calculations and work papers both to the Company and to Executive within ten (10) days of such date, and any such
determination by the Accounting Firm will be binding upon the Company and Executive.

 

    	 

     

    

 

7.7
DEFERRED COMPENSATION SUBJECT TO CODE SECTION 409A. Notwithstanding anything to the contrary set forth herein, any payments and benefits
provided under this Agreement that constitute “deferred compensation” within the meaning of Code Section 409A will not commence
in connection with Executive’s termination of employment unless and until Executive has also incurred a “separation from
service” (as such term is defined in Treasury Regulation Section 1.409A-1(h) (“Separation From Service”),
unless the Company reasonably determines that such amounts may be provided to Executive without causing Executive to incur additional
tax under Code Section 409A. It is intended that each installment of Severance Benefits provided for in this Agreement is a separate
“payment” for purposes of Treasury Regulation Section 1.409A-2(b)(2)(i). For the avoidance of doubt, it is intended that
Severance Benefits set forth in this Agreement satisfy, to the greatest extent possible, the exceptions from the application of Section
409A provided under Treasury Regulation Sections 1.409A-1(b)(4), 1.409A-1(b)(5), and 1.409A-1(b)(9). If the Company (or, if applicable,
the successor entity thereto) determines that any payments or benefits constitute “deferred compensation” under Code Section
409A and Executive is, on the termination of service, a “specified Executive” of the Company or any successor entity thereto,
as such term is defined in Section 409A(a)(2)(B)(i) of the Code, then, solely to the extent necessary to avoid the incurrence of the
adverse personal tax consequences to Executive under Section 409A, the timing of the payments and benefits will be delayed until the
earlier to occur of: (a) the date that is six (6) months and one day after Executive’s Separation From Service, or (b) the date
of Executive’s death (such applicable date, the “Specified Executive Initial Payment Date”). On the Specified
Executive Initial Payment Date, the Company (or the successor entity thereto, as applicable) will (i) pay to Executive a lump sum amount
equal to the sum of the payments and benefits that Executive would otherwise have received through the Specified Executive Initial Payment
Date if the commencement of the payment of such amounts had not been so delayed pursuant to this Section 7.7 and (ii) commence paying
the balance of the payments and benefits in accordance with the applicable payment schedules set forth in this Agreement.

 

8.
GENERAL PROVISIONS.

 

8.1
NOTICES. Any notice required or permitted under this Agreement will be given in writing by delivery in hand, express courier or by
postage prepaid, United States first class mail; registered or certified mail, return receipt requested; facsimile at the party’s
specified address; by email (including a confirmation of receipt); or as otherwise specified by a party. Notice will be effective upon
receipt.

 

8.2
RIGHT TO INJUNCTIVE RELIEF. Executive agrees and acknowledges that a violation of the covenants contained in Section 4 of this Agreement
will cause irreparable damage to the Company, and that it is and will be impossible to estimate or determine the damage that will be
suffered by the Company in the event of breach by Executive of any such covenant. Therefore, Executive further agrees that, in the event
of any violation or threatened violation of such covenants, the Company will be entitled to an injunction issued by any court of competent
jurisdiction restraining such violation or threatened violation by Executive, such right to an injunction to be cumulative and in addition
to whatever other remedies the Company may have.

 

8.3
Reserved

 

8.4
WAIVER. If either party should waive any breach of any provisions of this Agreement, such party will not thereby be deemed to have
waived any preceding or succeeding breach of the same or any other provision of this Agreement. It is agreed that no delay or omission
to exercise any right, power or remedy accruing to either party, upon any breach, default or noncompliance by the other party under this
Agreement will impair any such right, power or remedy, nor will it be construed to be a waiver of any such breach, default or noncompliance,
or any acquiescence therein, or of or in any similar breach, default or noncompliance thereafter occurring. It is further agreed that
any waiver, permit, consent or approval of any kind or character on either party’s part of any breach, default or noncompliance
under this Agreement or any waiver on such party’s part of any provisions or conditions of the Agreement must be in writing and
will be effective only to the extent specifically set forth in such writing. All remedies, either under this Agreement by law, or otherwise
afforded to either party, will be cumulative and not alternative.

 

8.5
WITHHOLDING. All amounts payable hereunder will be reduced by any and all federal, state, and local taxes imposed upon the Executive
that are required to be paid or withheld by the Company.

 

    	 

     

    

 

8.6
COMPLETE AGREEMENT. This Agreement constitutes the entire agreement between Executive and the Company with regard to the subject
matter hereof. This Agreement is the complete, final, and exclusive embodiment of the parties’ agreement with regard to this subject
matter and supersede any prior oral discussions or written communications and agreements, including but not limited to any previous agreements.
In the event of a conflict between this Agreement and any other agreement the provisions of this Agreement will control. This Agreement
is entered into without reliance on any promise or representation other than those expressly contained herein, and it cannot be modified
or amended except in writing signed by Executive and an authorized officer of the Company. The parties may enter into, or may have entered
into, separate agreement(s) related to stock options, stock awards or other matters relative to Executive’s service with the Company
or its affiliates. These separate agreements govern (or may govern) other aspects of the relationship between the parties, have or may
have provisions that survive termination of Executive’s employment under this Agreement, may be amended or superseded by the parties
without regard to this Agreement and are enforceable according to their terms without regard to the enforcement provision of this Agreement,
and it is not the intent of the Parties that this Agreement, the offer letter, or the Confidentiality Agreement modify or otherwise supersede
the terms of such separate agreements.

 

8.7
COUNTERPARTS. This Agreement may be executed in separate counterparts, including facsimile, PDF, or other electronic counterparts,
any one of which need not contain signatures of more than one party, but all of which taken together will constitute one and the same
Agreement.

 

8.8
HEADINGS. The headings of the sections hereof are inserted for convenience only and will not be deemed to constitute a part hereof
nor to affect the meaning thereof.

 

8.9
SUCCESSORS AND ASSIGNS. The Company may assign this Agreement and its rights and obligations hereunder in whole, but not in part,
to any company or other entity with or into which the Company may hereafter merge, consolidate, or be acquired by, or to which the Company
may transfer all or substantially all of its assets. Executive may not assign or transfer this Agreement or any rights or obligations
hereunder, other than to Executive’s estate upon Executive’s death.

 

8.10
CHOICE OF LAW / VENUE. All questions concerning the construction, validity and interpretation of this Agreement will be governed
by the internal, substantive laws of the State of Florida, as applied to agreements made and to be performed solely within the State
of Florida and without regard to the principles of conflicts of laws of the State of Florida or of any other jurisdiction that would
result in the application of the laws of any other jurisdiction to this Agreement. Any action brought to enforce this Agreement will
be brought in Florida in a court of competent jurisdiction.

 

8.11
ATTORNEYS’ FEES. In any action brought to enforce this Agreement, the substantially prevailing party in such dispute will be
entitled to recover from the losing party all reasonable fees, costs and expenses of enforcing any right of such substantially prevailing
party under or with respect to this Agreement, including without limitation, such reasonable fees and expenses of attorneys, which will
include, without limitation, all fees, costs and expenses of appeal.

 

[Remainder
of Page Intentionally Blank, Signature Page Follows]

 

    	 

     

    

 

IN
WITNESS WHEREOF, the parties have executed this Agreement on the day and year first written above.

 

	 Company:
    Scripps Safe, Inc. 	   
	   	   	   
	 Name:
     	 /s/
    Jacqueline von Zwehl 	   
	 Title:
     	 President
    and CEO 	   

 

[Signature
Page to Employment Agreement]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00351-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00351-of-00352.parquet"}]]